Payment overview · 2025
General Payments
$181.43
8 reported records · 5 companies
Healthcare provider profile · identity verified
Chaker H Diab, DO
Allopathic & Osteopathic Physicians|Internal Medicine · WARREN, MI · NPI 1477522381
Verified facts
What the public records show
CMS Open Payments records show Chaker H Diab, DO received $181.43 in general payments during 2025 across 8 reported records.
Novo Nordisk Inc accounted for 38.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $68.85 | 38.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.92 | 19.2% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.37 | 16.2% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.79 | 14.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.50 | 11.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $181.43 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $68.85 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $68.85 | 3 | 2025 |
Source payment records
|
|||||
| EDARBYCLOR Normalized: edarbyclor |
Drug | Azurity Pharmaceuticals, Inc. | $29.37 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $26.79 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 514 | 151 |
| Losartan Potassium | Losartan Potassium | 276 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 236 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 189 | 48 |
| Carvedilol | Carvedilol | 169 | 44 |
| Metformin Hcl | Metformin Hcl | 169 | 45 |
| Lisinopril | Lisinopril | 155 | 47 |
| Omeprazole | Omeprazole | 150 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 134 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 122 | 20 |
| Furosemide | Furosemide | 121 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 112 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 33 |
| Famotidine | Famotidine | 101 | 31 |
| Potassium Chloride | Potassium Chloride | 90 | 30 |
| Januvia | Sitagliptin Phosphate | 83 | 20 |
| Ozempic | Semaglutide | 83 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 31 |
| Sertraline Hcl | Sertraline Hcl | 79 | 19 |
| Gabapentin | Gabapentin | 78 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 78 | 33 |
| Methylprednisolone | Methylprednisolone | 76 | 57 |
| Eliquis | Apixaban | 73 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 28 |
| Ventolin Hfa | Albuterol Sulfate | 67 | 18 |
| Jardiance | Empagliflozin | 66 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 19 |
| Tramadol Hcl | Tramadol Hcl | 61 | 16 |
| Buspirone Hcl | Buspirone Hcl | 55 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 13 |
| Prednisone | Prednisone | 53 | 42 |
| Trazodone Hcl | Trazodone Hcl | 52 | 15 |
| Finasteride | Finasteride | 51 | 14 |
| Nifedipine Er | Nifedipine | 50 | 14 |
| Glipizide | Glipizide | 47 | 12 |
| Donepezil Hcl | Donepezil Hcl | 45 | 14 |
| Atenolol | Atenolol | 44 | suppressed |
| Simvastatin | Simvastatin | 44 | 13 |
| Ezetimibe | Ezetimibe | 42 | 14 |
| Glimepiride | Glimepiride | 41 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 37 | 13 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | 11 |
| Alprazolam | Alprazolam | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | 11 |
| Cefuroxime | Cefuroxime Axetil | 24 | 21 |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Nystatin | Nystatin | 20 | 11 |
| Topiramate | Topiramate | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 18 |
| Lorazepam | Lorazepam | 19 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Azithromycin | Azithromycin | 17 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 15 |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $181.43 · 8 records | Novo Nordisk Inc | Cologuard Collection Kit, EDARBYCLOR, GIVLAARI, KISUNLA, Ozempic, Rybelsus, The Cologuard Plus Collection Kit | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error